Bayer announced its sales target for the next two years at the investor conference on Wednesday, growing at least 6% annually, reaching $27 billion by 2017, and its core business revenue ratio will rise from 27.5% in 2014 to 29%- 31%. At the end of this year, the materials business unit will be divested or an independent IPO. The core of the company's business is in life sciences. This means that the medical business will be highly valued and it is highly probable that the talent team will be expanded.
Bayer now has five new potentials: the new generation of anticoagulant Xarelto, the ophthalmic drug Eylea, the anticancer drugs Stivarga and Xofigo, and Adempas for the treatment of pulmonary hypertension. Bayer predicts that these drugs will absorb at least 4 billion euros this year. In addition, consumer health care business sales will also grow at an average annual rate of 4%, reaching at least 10 billion euros in 2017. Despite the unsatisfactory OTC sales in the fourth quarter of 2014, Bayer CEO Marijn Dekkers explained that Bayer has just lifted its marriage with Merck's consumer healthcare business and has narrowed its business, which is a transitional phase.
Dekkers said that if the investment in new drug research and development is large, it is also possible to reduce profit margins. “The more drug product lines are developed, the more it is going to increase the investment in clinical trials,†he said at the investor conference.
Citigroup analyst Peter Verdult commented that Bayer's sales target is "a relatively conservative outlook." But for the Bayer crop, this goal is full of challenges. For the Bayer Consumer Healthcare business, this goal is equally daunting, especially since the Merck OTC drug business has just been cut.
Small Molecule Peptide,Collagen Peptide,Yam Peptide Powder,Herb Ginseng Peptide
Fufeng Sinuote Biotechnology Co.,Ltd. , https://www.sinuotebio.com